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channel blocker used in treatment of hypertension and 
angina pectoris.[1] Amlodipine is well absorbed following 
oral administration with peak blood concentrations 
occurring after 6–12 h. The bioavailability is about 
60–  65%. It has a prolonged terminal elimination half-life 
of 35–50 h, and steady-state plasma concentrations are not 
achieved until after 7–8 days of administration. Amlodipine 
is extensively metabolized in the liver; metabolites are 
mostly excreted in urine together with <10% of a dose 
as unchanged drug.[2,3] Several analytical methods for 
quantifying of amlodipine in biological fluids have been 
reported; such as capillary gas chromatography (GC) with 
electron capture detection,[4,5] GC with electron-impact 
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Amlodipine, R, S‑2‑[(2‑aminoethoxy)methyl]‑4‑
(2‑chlorophenyl)‑ethoxycarbonyl‑5‑methoxy‑carbonyl‑6‑
methyl-1, 4-dihydropyridine [Figure 1], is a potent calcium 
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AbSTRACT
A rapid, simple and sensitive high-performance liquid chromatography (HPLC) method has been developed for 
quantification of olmesartan medoxomil (OLM) and amlodipine besylate (AM) in plasma. The assay enables 
the measurement of OLM and AM for therapeutic drug monitoring with a minimum detectable limit of 2 ng mL. 
The method involves a simple, one-step extraction procedure and analytical recovery was above 50%. The 
separation was performed on an analytical 250 × 4.6 mm Eurospher 100-5 C18 column. The wavelength was set 
at 239 nm. The mobile phase was a mixture of acetonitrile:0.05 M ammonium acetate buffer: 0.1 mL triethylamine 
at pH 6.8 was selected at a flow rate of 1.0 mL min. The calibration curve for the determination of OLM and AM 
in plasma was linear over the range 2–2500 and 8–10,000 ng mL AM and OLM. The coefficients of variation 
for interday and intraday assay were found to be <15%. The method can be applied to a pharmacokinetic and 
pharmacodynamic study of OLM and AM in a combined dosage form.
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mass spectrometry (EI-MS),[6,7] and high-performance 
liquid chromatography (HPLC).[8-12] Several HPLC 
procedures have been also reported for the analyses of 
amlodipine based on MS–MS detection by using tandem 
mass spectrometry.[13-16] Olmesartan medoxomil (OLM), 
(5‑methyl‑2‑oxo‑1,3‑dioxolen‑4‑yl) methoxy‑4‑(1‑hydrox
y-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)-phenyl]
phenyl}methyl imidazol‑5‑carboxylate) [Figure 2], is a 
potent and selective angiotensin AT1 receptor blocker[17] 
which has been approved for the treatment of hypertension 
in the United States, Japan, and European countries. The 
drug contains a medoxomil ester moiety and is cleaved 
rapidly by an endogenous esterase to release the active 
metabolite olmesartan.[18] Up to date, olmesartan has been 
determined in plasma and other biological fluids using 
HPLC coupled to fluorescent detection.[19,20]
As per literature survey, no analytical methods have been 
reported for the simultaneous quantitative analysis of 
OLM and AM in biological fluid. The aim of our study 
was to develop a rapid, simple, accurate, precise, sensitive, 
and reproducible HPLC method, which can be utilized in 
pharmacokinetic research.
EXPERIMENTAL
Chemicals and reagents
Olmesartan medoxomil (OLM) and amlodipine besylate 
(AM) were kindly supplied by Ajanta Pharma Limited 
(Mumbai). All chemicals and reagents were HPLC grade, 
methanol and acetonitrile, ammonium acetate, ethylene 
diamine tetra acetic acid (EDTA) (Merck, India).
Instruments and chromatographic conditions
A Shimadzu HPLC system (Japan) employed consisted of 
a model LC-20 AT pump, a model Rheodyne 7125 injector, 
and a model SPD‑20A UV detector. The separation was 
performed on an analytical 250 × 4.6 mm Eurospher 
100-5 C18 (5 µm, particle size) column. The wavelength 
was set at 239 nm. The mobile phase was a mixture of 
acetonitrile:0.05 M ammonium acetate buffer: 0.1 mL 
triethylamine at pH 6.8 was selected at a flow rate of 
1.0 mL/min. The mobile phase was prepared daily and 
degassed by ultrasonification before use.
Preparation of standard stock solution
The standard working concentration of OLM (10 µg/mL) 
and AM (10 µg/mL) were prepared in the mobile phase.
Biological samples
The prepared suspension containing AM (0.4 mg/mL) and 
OLM (1.6 mg/mL) in 0.2% tween 80 were administered 
orally to Wistar rats (180–220 g) at a dose of 2 mg/kg (AM) 
and 8 mg/kg (OLM) body weight after overnight fasting. The 
blood samples were collected from the retrobulbar plexus 
into anticoagulant-treated polypropylene tubes from 0 to 
12 h after drug administration. Blood samples collected were 
centrifuged immediately to separate the plasma. The plasma 
samples collected were stored at −20°C. The plasma samples 
then processed for drug recovery via solvent extraction.
Samples preparation (extraction procedure)
To 1000 µL of plasma samples in a borosilicate glass tube 
were added 5 mL of HPLC grade acetonitrile. After vortex 
mixing for 10 min at room temperature, the samples were 
centrifuged at 10,500 rpm for 10 min. The upper organic 
layer was transferred to a glass container and evaporated 
inside a vacuum oven at 40°C. The dry residue was 
dissolved in 1 mL of the mobile phase. The mixture was 
sonicated well for 10 min, and 20 µL of this solution was 
injected into liquid chromatography.
Stability
Stability assessments were defined as the resistance to 
change in concentration of an analyte in plasma under 
Figure 1: Structure of amlodipine
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specified conditions. The stability of OLM and AM in rat 
plasma was investigated by adding known amount of drug 
to blank plasma samples to give concentrations of 10, 200, 
and 500 ng/mL. These were stored at -20°C and aliquots 
taken for 1 and 4 weeks for analysis.
Calibration curve
Linearity of instrument standard response was determined 
for each compound with different concentration 
calibration standards (final concentration ranging from 2 to 
2500 ng/mL for AM and 8 to 10,000 ng/mL for OLM, with 
drug ratio maintaining constant 1:4). The calibration curves 
were constructed by plotting individual analyte peak area 
ratio as compared to the corresponding concentration and 
fitting these data in regression analysis. The calibration curves 
were constructed by the weighted regression method (1/x) 
of the peak area of OLM or AM vs. actual concentrations.
RESULTS AND DISCUSSION
Method development
Considering the efficiency of HPLC, an attempt has 
been made to develop a simple, accurate, precise, rapid, 
and economic method for the simultaneous estimation 
of OLM and AM in the biological method. Thus, the 
method described enables to the quantification of OLM 
and AM. The advantages lie in the simplicity of sample 
preparation and the low costs of reagents used. For the 
HPLC method development mobile phase consists of 
acetonitrile:0.05 M ammonium acetate buffer:0.1 mL 
triethylamine at pH 6.8 at a flow rate of 1.0 mL/min. The 
optimum wavelength selected was 239 nm. Under these 
chromatographic conditions described, OLM and AM 
peaks were well resolved. Endogenous plasma components 
did not give any interfering peaks. The average retention 
times of OLM and AM were 3.1 and 5.0 min, respectively. 
Chromatogram obtained after drug administration of OLM 
and AM in Wistar rats for blank plasma and plasma samples 
collected after 2.5, 6 and 10 h are shown in Figure 3.
Calibration curve
The calibration curve for the determination of OLM 
and AM in plasma was linear over the range 2–2500 and 
8–10,000 ng/mL AM and OLM. The linearity of this 
method was statistically confirmed. For each calibration 
curve, the intercept was not statistically different from zero. 
The correlation coefficients (R) for calibration curves were 
equal to or better than 0.997. The relative standard deviation 
(RSD) values of the slope were equal to or better than 5%. For 
each point of calibration standards, the concentrations were 
recalculated from the equation of the linear regression curves.
Recovery study
The relative analytical recovery for plasma at three different 
concentrations of OLM and AM was determined. Known 
amounts of drug were added to drug-free plasma in 
concentrations ranging from 0.002 to 10 µg/mL. The 
average recovery was in between 50% and 90% for a linear 
concentration range. The results are given in Tables 1 and 2 
for the intraday and interday study.
Stability study
In the short-term stability studies, precision and accuracy 
for the analyte was <15% and <8% for OLM, <10% and 
8% for AM, respectively. In the long-term stability studies, 
precision and accuracy for the analyte was <7% and <15% 
Table 1: Recovery studies for olmesartan medoxomil and  amlodipine besylate (intraday) (RP-HPLC)
Sample 
no.
Drug Concentration 
added (µg mL)
Peak area 
of standard
Mean peak 
area samplea
% 
Recoverya
±SD CV
1 AM 0.002 1888.81 1645.1 87.1 4.14 4.75
OLM 0.008 1211.4 1069.5 88.29 4.43 5.02
2 AM 0.01 3739 3203.4 85.68 1.29 1.51
OLM 0.04 2265.1 1966.2 86.8 2.51 2.89
3 AM 0.05 5695.2 4020 70.59 4.7 6.66
OLM 0.2 11325.9 8689.2 76.72 2.82 3.68
4 AM 0.2 10781 8858.74 82.17 2.93 3.57
OLM 80 44638.13 35049.84 78.52 6.49 8.27
5 AM 0.5 26952.5 17387.9 64.51 3.16 4.9
OLM 2 113259.5 70583.26 62.32 5.66 9.08
6 AM 1.5 80857.5 38064.76 47.08 5.15 10.9
OLM 6 275224.5 135510.9 49.24 7.54 15.3
7 AM 2.5 134762.5 52579.76 39.02 2.55 6.54
OLM 10 436810.5 181465.2 41.54 4.25 10.2
OLM: Olmesartan medoxomil; AM: amlodipine besylate; aResults are mean of three samples, ICU-???, RP-HPLC-???, SD-standard deviationJournal of Young Pharmacists Vol 4 / No 2  91
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for OLM, <12% and 18% for AM, respectively. The 
stability tests indicated that OLM and AM are stable in rat 
plasma over the period of 1 month. In addition, the stock 
solution remains stable for a duration of 1 month when 
stored at 4°C expressed by the % variation <2% for both 
OLM and AM. The results are given in Tables 3 and 4 for 
OLM and AM, respectively.
Limit of detection
The limit of detection (LOD) was defined, as the 
amlodipine concentration that produced a signal-to-noise 
ratio greater than 3. The LOD in plasma was 2 ng/mL for 
AM and 8 ng/mL based upon this criterion. At this level, 
the RSD was lower than 15%.
Accuracy and precision
Intraday and interday assay performed to evaluate precision 
(% RSD) and accuracy. The coefficient of variation for 
intraday studies was between 2–14% and 3–17% for 
interday in rat plasma. The result suggests that within run 
and between run experiments, the precision and accuracy 
for the analyte met the acceptance criteria.
It does not require tedious derivatization or specialized 
detectors, making it readily amendable to routine laboratory 
use. However, this method is sensitive enough for drug 
monitoring and other purposes such as pharmacokinetic 
studies. We assessed the precision of the method by 
repeated analysis of plasma specimens containing 
known concentrations of amlodipine and olmesartan. 
The coefficients of variation were less than 15%, which 
is acceptable for the routine measurement of OLM and 
AM. The results for intraday and interday precision and 
accuracy studies are given in Tables 5 and 6.
Pharmacokinetic study
The results of pharmacokinetics analysis of OLM 
and AM are mentioned in Table 7. The mean plasma 
concentration–time curve of OLM and AM shows: 
Figure 3: Chromatogram of blank plasma, OLM, and AM after oral administration in rat plasma92   Journal of Young Pharmacists Vol 4 / No 2
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Table 5: Data for accuracy and precision studies (Intraday) (RP-HPLC)
Sample  
no.
Drug Concentration 
added (µg mL)
Peak area 
of standard
Mean concentration 
founda
±SD CV % deviation
1 AM 0.002 1888.81 0.0019 6.9 6.77 −0.05
OLM 0.008 1211.4 0.0079 2.4 2.34 −0.012
2 AM 0.01 3739 0.0099 6.0 5.51 −0.01
OLM 0.04 2265.1 0.0396 5.6 5.46 −0.01
3 AM 0.05 5695.2 0.051 3.3 3.25 0.028
OLM 0.2 11325.9 0.198 2.8 2.75 −0.008
4 AM 0.2 10781 0.198 3.5 3.44 −0.012
OLM 80 44638.1 0.78 7.0 7.03 −0.99
6 AM 0.5 26952.5 0.52 4.8 5.07 0.0304
OLM 2 113260 1.95 7.5 6.95 −0.022
7 AM 1.5 80857.5 1.54 10.9 12.16 0.028
OLM 6 275225 5.7 15.3 13.29 −0.0497
8 AM 2.5 134763 2.54 6.54 6.47 0.015
OLM 10 436811 10.66 10.2 11.13 0.065
aResults are mean of three samples, RP-HPLC-???, AM-amlodipine besylate, OLM-Olmesartan medoxomil 
Plasma concentration reached a maximum 2 h and 6 h 
for OLM and AM, after dosing with a level of 8 and 
2 mg kg body weight of OLM and AM, respectively. The 
value of pharmacokinetic parameters such as t1/2, Cmax 
and kel obtained reveals that there was less difference 
in the profile of a individual drug when administered 
simultaneously in a single oral dosage form. These results 
are agreement with the previous reports.[19,21,22] Plasma 
Table 2: Recovery studies for OLM and AM (interday) (RP-HPLC)
Sample 
no.
Drug Concentration 
added (µg/mL)
Peak area 
of standard
Mean peak 
area samplea
% 
Recoverya
±SD CV
1 AM 0.002 1789.56 1726.7 96.48 3.18 3.3
OLM 0.008 1045.65 1079.4 103.23 3.28 3.18
2 AM 0.5 25478.45 18597 72.98 5.14 7.05
OLM 2 112457.48 72914 64.83 7.24 11.2
3 AM 2.5 132486.97 53425 40.32 1.45 3.62
OLM 10 437849.98 259467 59.25 10.27 17.3
aResults are mean of three samples, AM-amlodipine besylate, OLM-Olmesartan medoxomil, SD-standard deviation, CV-???, RP-HPLC-??? 
Table 3: Stability of OLM in rat plasma (RP-HPLC)
Sample concentration (ng mL) Concentration found (%) ±SD Mean concentration (%)a CV % Deviation (inaccuracy)
Short-term stability for 24 h in plasma (−20°C)
10 124.5 101.5 95.2 15.42 107.06 14.4 7.06
200 91.62 101.18 100.9 5.44 97.9 5.55 2.1
500 97.25 97.62 102.57 2.97 99.14 2.99 0.852
Long-term stability for 1 month in plasma (−20°C)
10 96.5 88.4 101.12 6.43 95.34 6.75 4.64
200 87.82 80.12 90.67 5.45 86.20 6.33 13.79
500 90.57 95.07 88.91 3.18 91.51 3.48 8.41
aResults are mean of three samples, SD-standard deviation, CV-???, OLM-Olmesartan medoxomil, RP-HPLC-???  
Table 4: Stability of AM in rat plasma (RP-HPLC)
Sample concentration (ng mL) Concentration found (%) ±SD Mean concentration (%)a CV % Deviation (inaccuracy)
Short-term stability for 24 h in plasma (−20°C)
10 111.45 134.5 122.4 11.53 122.78 9.3 2.28
200 87.27 107.77 92.12 10.714 95.72 11.1 4.3
500 97.89 88.51 94.24 4.72 93.54 5.05 7.58
Long-term stability for 1 month in plasma (−20°C)
10 97.89 84.5 89.4 6.77 90.59 7.47 9.4
200 81.77 72.89 92.24 9.68 82.3 11.7 17.7
500 84.62 95.93 82.53 7.20 87.69 8.2 12.3
aResults are mean of three samples, AM-amlodipine besylate, SD-standard deviation, CV-???, RP-HPLC-??? Journal of Young Pharmacists Vol 4 / No 2  93
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concentration–time profile curve following a single oral 
administration of OLM and AM in a combined dosage 
form in Wistar rats is shown in Figure 4.
CONCLUSION
The HPLC method presented is direct, simple, selective, 
reproducible, sensitive, and linear. The procedure was 
successfully applied to the simultaneous determination 
of the studied compounds in biological fluid without any 
interference from the additives and endogenous substances. 
The procedure was fully validated to meet the requirements 
of the food and drug administration center for drug 
evaluation and research guidelines for bioanalytical method 
validation.[23] These methods are well-suited for routine 
application in the quality control laboratories and clinical 
laboratories because of the simplicity, economic, accuracy, 
sensitivity, and reproducibility. The HPLC method is 
applicable to pharmacokinetics studies of OLM and AM in 
rats. This method can also be used to study the mechanism 
of metabolism of OLM and AM.[24]
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